References
- Nowell P C, Hungerford D A. A minute chromosome in human chronic granulocytic leukaemia. Science 1960; 132: 1947
- Druker B J, Guilhot F, O'Brien S, Gathmann I, Kantarjian H, Gattermann N, et al. Five years follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med 2006; 355: 2408–2417
- Common terminology criteria for adverse events v3.0 (CTCAE). Ctep.cancer.gov/forms/CTCAEv3.pdf
- Breccia M, Cannella L, Frustaci A, Stefanizzi C, Levi A, Alimena G. Cardiac events in imatinib mesylate-treated chronic myeloid leukaemia patients: a single institution experience. Leuk Res 2008; 32: 835–836
- Breccia M, Gentilini F, Cannella L, Latagliata R, Carmosino I, Frustaci A, et al. Ocular side effects in chronic myeloid leukaemia patients treated with imatinib. Leuk Res 2008; 32: 1022–1027
- O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukaemia. N Engl J Med 2003; 348: 994–1004
- Deininger M WN, O'Brien S G, Ford J M, Druker B J. Practical management of patients with chronic myeloid leukaemia receiving imatinib. J Clin Oncol 2003; 21: 1637–1647
- Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N Engl J Med 2002; 346: 645–652
- Sneed T B, Kantarjian H, Talpaz M, O'Brien S G, Rios M B, Bekele B N, et al. The significance of myelosuppresion during therapy with imatinib mesylate in patients with chronic myelogenous leukaemia in chronic phase. Cancer 2004; 100: 116–121
- Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer C A, Cortes J, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukaemia after failure of interferon-alpha treatment. Blood 2008; 111: 1039–1043